Clene (CLNN) Competitors $8.89 +0.30 (+3.49%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$8.91 +0.02 (+0.22%) As of 10/15/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. EOLS, ALMS, ETHZ, LRMR, ACIU, FDMT, ENGN, KMDA, YMAB, and AMRNShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Evolus (EOLS), Alumis (ALMS), Flag Ship Acquisition (ETHZ), Larimar Therapeutics (LRMR), AC Immune (ACIU), 4D Molecular Therapeutics (FDMT), enGene (ENGN), Kamada (KMDA), Y-mAbs Therapeutics (YMAB), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Clene vs. Its Competitors Evolus Alumis Flag Ship Acquisition Larimar Therapeutics AC Immune 4D Molecular Therapeutics enGene Kamada Y-mAbs Therapeutics Amarin Clene (NASDAQ:CLNN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do analysts rate CLNN or EOLS? Clene currently has a consensus target price of $32.60, suggesting a potential upside of 266.70%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 221.48%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Evolus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility & risk, CLNN or EOLS? Clene has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Does the media prefer CLNN or EOLS? In the previous week, Evolus had 2 more articles in the media than Clene. MarketBeat recorded 8 mentions for Evolus and 6 mentions for Clene. Clene's average media sentiment score of 0.97 beat Evolus' score of 0.50 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, CLNN or EOLS? Clene has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$340K263.30-$39.40M-$3.76-2.36Evolus$277.94M1.54-$50.42M-$0.98-6.74 Do insiders & institutionals have more ownership in CLNN or EOLS? 23.3% of Clene shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 35.3% of Clene shares are owned by company insiders. Comparatively, 5.9% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CLNN or EOLS more profitable? Evolus has a net margin of -22.31% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Clene-10,386.36% N/A -125.49% Evolus -22.31%-759.04%-24.63% SummaryClene beats Evolus on 9 of the 16 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricCleneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.50M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-2.3622.7785.3627.36Price / Sales263.30486.00596.99137.58Price / CashN/A46.7037.4661.86Price / Book-8.3910.5512.286.81Net Income-$39.40M-$52.58M$3.32B$276.80M7 Day Performance-5.83%0.09%0.59%0.42%1 Month Performance40.44%15.61%10.54%7.86%1 Year Performance56.79%15.13%70.62%41.24% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.0758 of 5 stars$8.89+3.5%$32.60+266.7%+52.0%$86.50M$340K-2.36100News CoverageAnalyst ForecastEOLSEvolus4.0378 of 5 stars$6.43-1.1%$21.25+230.5%-60.4%$420.45M$266.27M-6.56170Analyst ForecastALMSAlumis3.5648 of 5 stars$4.12+2.5%$20.17+389.5%-56.7%$418.34MN/A0.00N/AETHZFlag Ship AcquisitionN/A$2.55+0.8%N/AN/A$416.01MN/A-0.177News CoverageStock SplitGap DownLRMRLarimar Therapeutics2.968 of 5 stars$4.81-1.2%$16.71+247.5%-42.9%$403.13MN/A-3.0830ACIUAC Immune1.7988 of 5 stars$3.54-11.3%$10.00+182.5%-4.1%$400.64M$28.92M-6.10140Positive NewsHigh Trading VolumeFDMT4D Molecular Therapeutics2.4841 of 5 stars$8.40-1.8%$30.40+261.9%+12.0%$399.31M$40K-2.38120ENGNenGene2.9047 of 5 stars$7.60-1.9%$19.50+156.6%+4.8%$396.74MN/A-4.0031Analyst ForecastKMDAKamada4.5623 of 5 stars$6.70-1.8%$13.00+94.0%+25.2%$392.18M$160.95M19.71360YMABY-mAbs Therapeutics1.1743 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150AMRNAmarin0.4666 of 5 stars$19.33+2.6%$12.00-37.9%+73.5%$389.66M$228.61M-5.27360News CoverageHigh Trading Volume Related Companies and Tools Related Companies EOLS Competitors ALMS Competitors ETHZ Competitors LRMR Competitors ACIU Competitors FDMT Competitors ENGN Competitors KMDA Competitors YMAB Competitors AMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
